Literature DB >> 8914736

Possible new variant of Nijmegen breakage syndrome.

V M Der Kaloustian1, W Kleijer, A Booth, A D Auerbach, B Mazer, A M Elliott, S Abish, R Usher, G Watters, M Vekemans, P Eydoux.   

Abstract

We report on a child with microcephaly, small facial and body size, and immune deficiency. The phenotype is consistent with Nijmegen breakage syndrome (NBS), with additional clinical manifestations and laboratory findings not reported heretofore. Most investigations, including the results of radiation-resistant DNA synthesis, concurred with the diagnosis of NBS. Cytogenetic analysis documented abnormalities in virtually all cells examined. Along with the high frequency of breaks and rearrangements of chromosomes 7 and 14, we found breakage and monosomies involving numerous other chromosomes. Because of some variation in the clinical presentation and some unusual cytogenetic findings, we suggest that our patient may represent a new variant of Nijmegen breakage syndrome.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8914736     DOI: 10.1002/(SICI)1096-8628(19961002)65:1<21::AID-AJMG3>3.0.CO;2-0

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  10 in total

Review 1.  Immunodeficiency associated with DNA repair defects.

Authors:  A R Gennery; A J Cant; P A Jeggo
Journal:  Clin Exp Immunol       Date:  2000-07       Impact factor: 4.330

2.  Nijmegen breakage syndrome with macrocephaly, schizencephaly and large CSF spaces—extended spectrum of the condition.

Authors:  Krzysztof Szczałuba; Hanna Mierzewska; Ewa Obersztyn; Jolanta Tryfon; Monika Bekiesińska-Figatowska; Elzbieta Szczepanik; Krystyna Chrzanowska; Ewa Bocian
Journal:  J Appl Genet       Date:  2012-05       Impact factor: 3.240

Review 3.  Nijmegen breakage syndrome. The International Nijmegen Breakage Syndrome Study Group.

Authors: 
Journal:  Arch Dis Child       Date:  2000-05       Impact factor: 3.791

4.  Role of Nijmegen breakage syndrome protein in specific T-lymphocyte activation pathways.

Authors:  M A García-Pérez; L M Allende; A Corell; E Paz-Artal; P Varela; A López-Goyanes; F García-Martin; R Vázquez; A Sotoca; A Arnaiz-Villena
Journal:  Clin Diagn Lab Immunol       Date:  2001-07

5.  Autozygosity mapping of a seckel syndrome locus to chromosome 3q22. 1-q24.

Authors:  J Goodship; H Gill; J Carter; A Jackson; M Splitt; M Wright
Journal:  Am J Hum Genet       Date:  2000-07-11       Impact factor: 11.025

6.  Abnormalities in the T and NK lymphocyte phenotype in patients with Nijmegen breakage syndrome.

Authors:  J Michałkiewicz; C Barth; K Chrzanowska; H Gregorek; M Syczewska; C M B Weemaes; K Madaliński; J Stachowski
Journal:  Clin Exp Immunol       Date:  2003-12       Impact factor: 4.330

7.  Fine localization of the Nijmegen breakage syndrome gene to 8q21: evidence for a common founder haplotype.

Authors:  K M Cerosaletti; E Lange; H M Stringham; C M Weemaes; D Smeets; B Sölder; B H Belohradsky; A M Taylor; P Karnes; A Elliott; K Komatsu; R A Gatti; M Boehnke; P Concannon
Journal:  Am J Hum Genet       Date:  1998-07       Impact factor: 11.025

Review 8.  Nijmegen breakage syndrome (NBS).

Authors:  Krystyna H Chrzanowska; Hanna Gregorek; Bożenna Dembowska-Bagińska; Maria A Kalina; Martin Digweed
Journal:  Orphanet J Rare Dis       Date:  2012-02-28       Impact factor: 4.123

9.  p38 (MAPK) stress signalling in replicative senescence in fibroblasts from progeroid and genomic instability syndromes.

Authors:  Hannah S E Tivey; Amy J C Brook; Michal J Rokicki; David Kipling; Terence Davis
Journal:  Biogerontology       Date:  2012-10-31       Impact factor: 4.277

10.  Nbn and atm cooperate in a tissue and developmental stage-specific manner to prevent double strand breaks and apoptosis in developing brain and eye.

Authors:  Paulo M G Rodrigues; Paulius Grigaravicius; Martina Remus; Gabriel R Cavalheiro; Anielle L Gomes; Maurício Rocha-Martins; Mauricio R Martins; Lucien Frappart; David Reuss; Peter J McKinnon; Andreas von Deimling; Rodrigo A P Martins; Pierre-Olivier Frappart
Journal:  PLoS One       Date:  2013-07-30       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.